Ivermectin 1% Cream
Therapeutic Cheat Sheet

**TRADE NAMES**

› Soolantra

**FDA APPROVED FOR**

› Inflammatory lesions of rosacea

**DOSING**

› One application to the affected area daily.

**Mechanism**

Exerts an anti-inflammatory effect by downregulating expression of TNFα and IL-1β while upregulating expression of IL-10.

Exerts anti-parasitic effects by binding glutamate-gated ion channels, allowing for an influx of chloride ions.

**Off-label uses**

Demodicosis, ocular rosacea

**Potential side effects**

While side effects are rare, burning, skin irritation and dermatitis have been reported.

**Results**

› In two pivotal phase III randomized control trials, ivermectin 1% cream demonstrated efficacy over vehicle with 38.4% and 40.1% of patients in the treatment groups reaching an endpoint of “clear” or “almost clear” vs 11.6% and 18.8% in patients treated with vehicle alone after 12 weeks. 76.0% and 75.0% of patients in the treatment arms showed a decrease in inflammatory lesion count from baseline vs 50.0% for both vehicle groups.

› In two 40-week extension studies, ivermectin 1% cream showed continued efficacy and less adverse events when compared to azelaic acid 15% gel (1.9% vs 6.7% in study 1 and 2.1% vs 5.8% in study 2).

**Considerations**

› It has been posited that nightly application may be beneficial, since *Demodex folliculorum* migrate nocturnally.

› There have been reports of successful treatment of ocular rosacea with daily application of ivermectin 1% cream to the closed eyelids.